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3ABSTRACT
Neurotransmitters and neurosteroids are compounds that regulate the
functions of the brain. The neurotransmitters dopamine (DA) and serotonin
(5-HT) play  a  role  in  several  psychological  conditions,  including
schizophrenia,  depression  and  anxiety.  DA  also  has  an  important  role  in
Parkinson’s disease. Neurosteroids are involved in neurodegenerative
diseases. In Alzheimer’s disease and multiple sclerosis, the levels of
neurosteroids are decreased in certain areas of the brain. Neurosteroids differ
from classical neurotransmitters in that they are lipid-soluble and can easily
cross the blood-brain barrier (BBB).
Neurotransmission  can  be  studied  in  vivo  by  microdialysis,  but  as  the
concentrations  of  neurotransmitters  in  the  microdialysates  are  very  low,
sensitive  analytical  methods  are  needed  for  their  analysis.  In  this  work  an
UPLC-MS/MS method was developed for the determination of 5-HT, DA, their
phase I metabolites 5-HIAA, DOPAC and HVA, and their sulfonate and
glucuronide conjugates. The method was validated and applied for analyzing
human brain microdialysis and cerebrospinal fluid (CSF) samples. Intact
glucuronide and sulfate conjugates were identified and quantified for the first
time in the human brain.
The origin of  the determined phase II  metabolites in the brain is  unknown.
Even though sulfonate-conjugated compounds such as dopamine sulfonate
(DA-S) and 5-HIAA-S were detected in the human brain, it is unclear whether
they were locally formed or transported into the brain through the BBB from
peripheral  sources.  The  BBB  permeation  of  DA-S  was  studied  by
administration of isotope (13C6)-labelled DA-S, which can be distinguished
from  endogenous  DA-S  by  mass  spectrometry,  subcutaneously  (s.c.)  while
brain microdialysis samples were collected and analyzed by UPLC-MS/MS.
The fate of 13DA-S  in  brain  was  followed  by  monitoring 13C6-labelled DA-S
metabolites and hydrolysis products. The results proved that DA-S permeates
through the BBB, and indicated that DA-S finally either permeates through the
BBB  back  to  the  peripheral  circulation  or  is  dissociated  or  metabolized  by
unknown mechanisms.
While  the  hydrophilic  neurotransmitters  DA  and  5-HT  are  well  suited  for
analysis  by  liquid  chromatography  coupled  to  atmospheric  pressure
ionization, the neurosteroids have more commonly been analyzed by methods
based on gas chromatography (GC) coupled to ionization in vacuum. Recently
GC has been combined to atmospheric pressure photoionization utilizing
heated nebulizer microchips (μAPPI). We now constructed a simpler interface
for  combining  GC  to  mass  spectrometry  (MS)  using  dopant-assisted
4atmospheric pressure photoionization (APPI), utilizing commercially
available hardware. The neurosteroids were analyzed as trimethylsilyl (TMS)
derivatives, and the effect of different dopants (chlorobenzene, toluene and
anisole)  on  the  ionization  and  on  the  sensitivity  of  the  method  was
investigated.  Chlorobenzene  was  chosen  as  the  best  dopant,  as  the
neurosteroid-TMS  derivatives  formed  intense  molecular  ions  with  minimal
fragmentation, while with toluene and anisole also protonated molecules were
observed. The molecular ions of the steroids formed by APPI ionization
showed fragmentation patterns in their MS/MS spectra similar to the patterns
seen in corresponding spectra obtained by electron impact ionization (EI).
Therefore  the  use  of  EI  libraries  could  be  possible,  thus  enabling  the
identification of a wide range of unknown compounds.
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ABBREVIATIONS
Ach acetylcholine
A aldosterone (11β,21-dihydroxy-pregn-4-ene-3,18,20-trione)
AP  allopregnanolone/ tetrahydroprogesterone (3α-hydroxy-5α-
pregnen-20-one)
AN androstenedione (androst-4-ene-3,17-dione)
API atmospheric pressure ionization
APCI atmospheric pressure chemical ionization
APPI atmospheric pressure photoionization
μAPPI miniaturized atmospheric pressure photoionization
Ch choline
CI chemical ionization
CNS central nervous system
CORT corticosterone (11β,21-dihydroxypregn-4-ene-3,20-dione)
CPI capillary photoionization
CS cortisone (17α,21-dihydroxypregn-4-ene-3,11,20-trione)
CSF cerebrospinal fluid
DA dopamine
DA-S dopamine sulfonate
DA-3-S dopamine-3-sulfate
DA-4-S dopamine-4-sulfate
13DA-3-S 13C6-dopamine-3-sulfate
13DA-4-S 13C6-dopamine-4-sulfate
11-DC 11-deoxycortisol (17,21-dihydroxypregn-4-ene-3,20-dione)
DHEA dehydroepiandrosterone (3β-hydroksiandrost-5-en-17-one)
5α-DHP 5α-dihydroprogesterone (5α-pregnane-3,20-dione)
DHT dihydrotestosterone (17β-hydroksi-5α-androstan-3-one)
DTE dithioerythritol
E epinephrine, adrenaline
EC electrochemical detection
EI electron impact ionization
ESI electrospray ionization
E2 β-estradiol (estra-1,3,5-triene-3,17β-diol)
E3 estriol (estra-1,3,5(10)-triene-3,16α,17β-triol)
E1 estrone (3-hydroxyestra-1,3,5(10)-trien-17-one)
FL fluorescence
GABA γ-aminobutyric acid
Glu glutamate
HC  hydrocortisone/ cortisol (11β,17α,21-trihydroksipregn-4-ene-
3,20-dione)
HILIC hydrophilic interaction liquid chromatography
IE ionization energy
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IP isopregnanolone (3β-hydroxy-5α-pregnen-20-one)
5-HT serotonin
LLE liquid-liquid extraction
LOD limit of detection
MS mass spectrometry
MS/MS tandem mass spectrometry
MSTFA N-Methyl-N-(trimethylsilyl)trifluoroacetamide
MT methyltestosterone (androst-4-en-3-one)
NE norepinephrine (noradrenaline)
NH4I ammonium iodide
PA proton affinity
PAPS 3’-phosphoadenosine 5’-phosphosulfate
PREG pregnenolone (3β-hydroksipregn-5-en-20-one)
17-OH-PREG 17-hydroxypregnenolone (3β,17α-dihydroxypregn-5-en-20-
one)
PROG progesterone (pregn-4-en-3,20-dione)
RP reversed-phase chromatography
s.c. subcutaneous
SPE solid-phase extraction
SIM selected ion monitoring
SRM selected reaction monitoring
SULT sulfotransferase
T testosterone (17β-hydroksiandrost-4-en-3-oni)
TMS trimethylsilyl
5α-THDOC  5α-tetrahydrodeoxycorticosterone (3α,21-dihydroxy-5α-
pregnan-20-one)
UDPGA Uridine 5’–diphospho glucuronic acid
UGT UDP-glucuronosyltransferase
UHPLC/UPLC ultra-high pressure liquid chromatography
VUV vacuum ultraviolet
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1 INTRODUCTION
Neurons (nerve cells) form the building blocks of the central nervous system
(CNS). Together, the billions of neurons in the brain communicate and process
information through highly organized networks. The nerve impulse is
transferred from a neuron to another with the help of neurotransmitters,
which  are  endogenous  chemicals  that  transmit  signals  from  a  neuron  to  a
target cell across a synapse. Neurotransmitters are involved in maintaining the
normal function of  the brain,  such as sleep and consciousness,  as  well  as  in
some brain disorders, such as Parkinson’s disease, epilepsy, schizophrenia,
depression,  anxiety,  and  dementia.  The  brain  and  the  spinal  cord  together
constitute  the  CNS,  which  lies  inside  the  skull  and  the  vertebral  canal.  A
physical and biochemical barrier, the blood-brain barrier (BBB) formed by the
capillary endothelial cells, prevents the access of many substances to the brain.
Due to the BBB, the development of new drugs to target brain-related diseases
proves challenging, since the BBB prevents entry into the brain of most drugs
and endogenous compounds from the blood. Only small lipophilic compounds
can diffuse passively through the BBB, while other compounds are usually only
able to cross the BBB with the help of carrier proteins [1,2].
There are several groups of neurotransmitters with different chemical
structures, including: monoamines (serotonin, 5-HT) and catecholamines
(dopamine, DA and noradrenaline, NE), choline esters (acethylcholine, Ach),
amino acids (glutamate, Glu and aspartate, Asp), γ-aminobutyric acid (GABA),
peptides, and steroids [3]. As the neurotransmitters are involved both in the
normal and pathological conditions of the brain, it is essentially important to
develop methods by which they can be analyzed and quantitated in biological
samples.
1.1 NEUROTRANSMITTERS AND NEUROSTEROIDS
Most neurotransmitters are synthezised from precursors in the axon terminals
in  the  CNS,  stored  in  vesicles  and  released  to  a  synaptic  cleft  between  the
presynaptic and postsynaptic neurons. To terminate the signal,
neurotransmitters are removed from the synaptic cleft by active uptake
mechanisms or they are enzymatically broken down. DA and 5-HT are two of
the main monoamine neurotransmitters in the brain. 5-HT is involved in the
regulation of several physiological functions, including the sleep-wake cycles,
body temperature, blood pressure, perception of pain, hormonal functions of
the  hypothalamus,  and  psychological  functions,  such  as  depression  and
anxiety [4,5],  while  DA  has  a  role  in  Parkinson’s  disease,  schizophrenia,
depression, and the regulation of motoric movements [6,7].
INTRODUCTION
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Neurosteroids are generally classified as steroids with local function in the
brain. They differ from other neurotransmitters in that they are lipid-soluble
and can easily cross the BBB, and can therefore be formed in the brain in situ
or in the periphery [3,8]. Peripherally formed neurosteroids are the
corticosteroids, corticosterone (CORT) and aldosterone (A), as well as
testosterone (T) and estradiol(E2); neurosteroids formed both in the
periphery and the CNS are progesterone (PROG), allopregnenolone (AP), and
pregnenolone (PREG), while the neurosteroid dehydroepiandrosterone
(DHEA) found in the CNS is formed locally in the CNS. Steroids formed in the
periphery  with  local  function  in  the  brain  are  sometimes  called  neuroactive
steroids, and only those formed in the brain in situ neurosteroids, but in this
thesis the term neurosteroid will be used for all steroids with local function in
the CNS. The neurosteroids exert their effects by binding to the intracellular
nuclear steroid receptors, but also by interaction with neurotransmitter-gated
ion channels and membrane steroid receptors [9–11]. Neurosteroids regulate
several cerebral functions, including protein synthesis, gene activation, and
activity  of  the  brain  through  the  activation  of  gamma-aminobutyric  acid
(GABA)  and  N-methyl-D-aspartate  (NMDA)  receptors,  as  well  as  nicotinic,
muscarinic and serotonergic receptors [11,12]. Neurodegenerative diseases have
been shown to alter neurosteroid levels. In Alzheimer’s disease and multiple
sclerosis, for example, the levels of neurosteroids are decreased in certain
areas of the brain [13].
1.1.1 PHASE I METABOLISM
5-HT is synthesized from the amino acid tryptophan, while the synthesis of DA
starts  from  tyrosine.  Both  DA  and  5-HT  are  metabolized  by  monoamine
oxidase (MAO) to the phase I metabolites 3,4-dihydroxyphenylacetic acid
(DOPAC) and 5-hydroxyindoleacetic acid (5-HIAA), respectively. DOPAC is
further metabolized to homovanillic acid (HVA) by catechol-O-
methyltrasferase (COMT) (Figure 1). Both DA and 5-HT, and their respective
metabolites, can undergo conjugation with glucuronic acid or sulfonate
mediated by catalysis with UDP-glucuronosyltransferases (UGTs) and
sulfotransferases (SULTs), respectively.
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Figure 1 Structures of the studied neurotransmitters and their phase I metabolites, as well as
the sulfate conjugate of DA and glucuronide conjugate of 5-HT-G.
All  steroids  are  biosynthesized  from  cholesterol;  the  neurosteroids  are
biosynthesized from cholesterol or from steroidal precursors imported from
peripheral sources [8,14]. The rate-limiting step in the synthesis of steroid
hormones is the conversion of cholesterol to pregnenolone. The neurosteroids
are  mainly  metabolised  by  cytochrome  P450  oxidase  enzymes,  such  as
CYP3A4,  to  other  steroids  (Figure  2).  Several  enzymes  involved  in  the
metabolism of steroids, such as 5α-reductase, 3α-hydroxysteroid
dehydrogenase and 17β-hydroxysteroid dehydrogenase, are present in the
human brain [15].
1.1.2 PHASE II METABOLISM: CONJUGATION WITH GLUCURONIC
ACID OR SULFONATE
The UGTs are a family of enzymes that catalyze the glucuronidation of various
compounds, and have an important role in the detoxification of a large number
of xenobiotic and endogenous compounds [16,17]. Many UGTs are expressed
mainly in the liver, but UGTs are also expressed in other organs, and some of
the UGTs are expressed only, or mainly, in extra-hepatic tissues, such as the
gastrointestinal tract, the olfactory mucosa, adipose tissue, and the kidneys.
Small amounts of UGT mRNA have also been found in several other tissues,
including the heart, adrenal gland, trachea and brain [17–19]. The UGTs catalyze
the transfer of glucuronic acid from UDPGA to various compounds, in order
to make the compounds more hydrophilic and thus easier to eliminate from
the body.
INTRODUCTION
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Figure 2 Biotransformation routes for selected steroids. Modified from [20].
Another family of  enzymes,  the SULTs,  catalyze the sulfonation of  different
compounds,  and  are  equally  important  in  the  metabolic  conjugation  of
xenobiotics  and  endogenous  compounds.  There  are  13  different  human
sulfotransferases that can be divided into three families, SULT1, SULT2, and
SULT4. Similar to that of the UGTs, the expression of SULTs is tissue-specific.
The liver is the most abundant site for most SULTs expression, although the
intestine,  lung,  kidney,  and  brain  also  express  SULTs [21,22].  The  SULTs
catalyse the transfer of a sulfonate group from 3’-phosphoadenosine-5’-
phosphosulfate (PAPS) to various compounds, mainly attaching the sulfonate
group to hydroxyl or primary amine groups [23].
Intact glucuronide conjugates of DA and 5-HT, and sulfonate conjugates of
their phase I metabolites DOPAC, HVA, and 5-HIAA have been found in rat
brain [24],  and  intact  sulfates  of  5-HIAA  and  DA  in  human  brain [25]. The
glucuronide and sulfate conjugates have been considered inactive, but recently
the  activity  of  glucuronide  and  sulfate  conjugates  of  a  few  substances  have
been shown. The glucuronide or sulfate conjugates of DHEA, PREG [26,27], and
morphine [28,29] are thought to be more active than the parent compounds in
modulating  their  pharmacological  effects  in  the  CNS.  The  neurosteroid
dehydroepiandrosterone (DHEA) also has an active conjugated metabolite,
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DHEA sulfate,  which  is  thought  to  be  involved  in  several  physiological  and
neuroprotective  processes  as  well  as  in  the  regulation  of  the  excretion  of
catecholamines [26].  The  glucuronidation  of  steroids  has  been  suggested  to
have neuroprotective effects by eliminating high steroid concentrations that
have been linked, for instance, to breast cancer [30], and DA sulfonation has
been suggested to serve as a  transport  form of  DA into cells,  where free DA
could be regenerated [31].
1.2 ANALYSIS OF NEUROTRANSMITTERS
The concentration of neurotransmitters can be sampled directly in vivo from
different parts of the brain using different techniques; microdialysis is the
most common. Neurotransmission can also be studied in brain tissue, which
enables the study of  different regions of  the brain,  but has to be performed
post mortem in most cases. In addition, cerebrospinal fluid (CSF) can also be
analyzed, but CSF concentrations reflect average concentrations accumulated
from all brain regions, and analysis of a specific brain area is not possible. In
animal  studies,  often  in  rats,  it  is  possible  to  select  the  appropriate  matrix
based on the researcher’s needs. In humans, however, the use of ventricular
CSF, brain tissue, or microdialysis of the extracellular fluid are possible only
during certain neurosurgical operations or post mortem. Lumbar puncture is
the most important and widely used diagnostic tool in the study of monoamine
metabolite concentrations in humans [32].
1.2.1 BRAIN EXTRACELLULAR FLUID
When neurotransmitters are released, a small fraction leaks out of the synaptic
clefts to the extracellular matrix. Thus, the concentration of a
neurotransmitter in the extracellular fluid is a relatively reliable measure of a
particular neuronal activity [33].  The  concentration  of  neurotransmitters  in
brain extracellular fluid have been measured by different techniques.
Prior to the use of microdialysis, other in vivo techniques were employed,
such as the cortical cup, which is a cylinder that is placed above a small hole in
the studied animal’s head, and enables sampling of chemicals released on the
surface of the cortex. The extracellular levels of AK, GABA, and Glu have been
determined by the cortical cup method [34–36],  but  the  drawback  to  this
method is that it is limited to only a certain region of the brain.
In  voltammetry,  an  electrode  is  placed  in  the  tissue  examined  and  the
current caused by oxidation of analytes is proportional to their concentration.
Fast-scan cyclic voltammetry makes measurements of changes in the
extracellular  level  of  dopamine  or  other  monoamines  at  millisecond  time
resolution  possible.  The  narrow probes  (diameter  5–20 μm) cause  minimal
tissue damage, but the drawbacks are relatively poor sensitivity and selectivity.
Voltammetric measurements are usually in the μM or high nM concentrations
INTRODUCTION
18
range, and thus do not allow assessment of basal levels [37]. The technique is
limited  to  analytes  that  are  electroactive  and  can  be  oxidized,  such  as
monoamines. Fast-scan cyclic voltammetry is a differential technique and thus
only changes in analyte concentration can be measured; the technique is not
suited for measuring long-term changes or constant basal concentrations [38].
Another drawback to voltammetry is that no drugs or other substances can be
locally applied in the tissue examined [39].
Push-pull  perfusion  can  be  considered  to  be  a  precursor  to  the
microdialysis technique. It includes two cannulas implanted in a certain brain
region, using an open flow system. Various substances can be sampled and
detected  by  this  technique,  and  it  has  been  used  for  sampling  of
neurotransmitters and other endogenous substances. The push–pull
perfusion method is an open system where the perfusion fluid directly contacts
the tissue under study at the tip. In earlier designs the size of the probe and
the flow at the tip often caused tissue damage or bacterial contamination at
the site of perfusion [40]. However, to overcome this problem, miniaturized
push–pull cannulae have been constructed utilizing low nl/min flowrates for
successful analysis of  Ach, 5-HT, DA, GABA, Glu, and Asp [41,42].
In  microdialysis  a  cannula  with  a  tip  covered  with  a  semipermeable
membrane is used. An advantage compared to the push-pull technique is that
the perfusion fluid (artificial CSF) does not come directly into contact with the
extracellular fluid. The dialysis membrane is permeable to small molecules but
not to macromolecules such as proteins. Endogenous compounds are sampled
via the probe, because the levels of neurotransmitters and metabolites are
higher in the extracellular space than in the perfusion fluid [43,44]. A drawback
of microdialysis is the fact that the recovery of the measured substances in the
microdialysis probe can be low and differ according to the dialyzed molecule.
Due  to  the  low  flow  rates  used,  time  resolution  is  low,  samples  are  usually
collected in a time frame of 20-30 minutes [39,40]. The small sample volumes
and the fact that the concentrations of most neurotransmitters are in the pM
or low nM range leads to a demand for highly sensitive analysis techniques,
such as LC-MS/MS.
Microdialysis has been largely used in the analysis of neurotransmitters
and  their  metabolites  in  the  central  nervous  system  of  laboratory  animals,
mainly in rats and mice [24,45–52]. In the human brain microdialysis has been
used to monitor neurointensive care patients with subarachnoid hemorrhage,
traumatic brain injury, thromboembolic stroke, or epilepsy [53–56].
Microdialysis of the human brain has also been performed in order to sample
extracellular dopamine in the human amygdala during the performance of
cognitive tasks in patients undergoing evaluation for epilepsy surgery [57],
during thalamotomy intended to relieve tremor in patients with Parkinson's
disease [58], in patients undergoing deep brain stimulation surgery for
advanced Parkinson’s disease [59], in patients with pharmacologically
intractable seizures that underwent implantation of intracranial depth
electrodes [60],  and  in patients  with  severe  head  injuries  or  subarachnoid
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haemorrhage,  in  which  microdialysis  probes  were  placed  together  with  a
ventriculostomy catheter for drainage of CSF [61].
1.2.2 CEREBROSPINAL FLUID
In addition to the brain extracellular fluid, neurotransmitters have commonly
been analysed in the CSF, especially in humans [53,62–67]. CSF is produced
mainly from arterial  blood by the choroid plexuses of  the lateral  and fourth
ventricles  of  the  brain.  Around  80%  of  the  CSF  is  secreted  by  the  choroid
plexuses,  with  the  remaining  20%  coming  from  the  interstitial  fluid  of  the
brain.  The  epithelial  cells  in  the  choroid  plexuses,  and  the  tight  junctions
between them, form the blood-CSF barrier. At the blood-CSF barrier, some
transporter proteins similar to those at the BBB have been identified [1,68–70].
The monoamine metabolite concentrations in the CSF reflect average
concentrations accumulated from all brain regions together with the regional
changes that occur within the spinal cord. Some neurotransmitters, such as 5-
HIAA and HVA,  have  a  rostrocaudal  gradient,  i.e.  the  concentrations  differ
depending on the site of sampling and changes if multiple samples are drawn
from the lumbar section [32,71,72]. The CSF contains several proteins that can
also be found in plasma, such as albumin, although at smaller concentrations
[69,73].
1.2.3 SAMPLE PRETREATMENT
Neurotransmitters such as serotonin, dopamine, and their metabolites are
small hydrophilic compounds, and have thus been analysed mostly by analysis
techniques  based  on  liquid  chromatography  with  electrochemical  or  mass
spectrometric detection.
Microdialysis  samples  require  virtually  no  pretreatment,  but  if  MS
detection  is  used,  the  inorganic  salts  of  the  artificial  CSF used  as  perfusion
fluid have to be prevented from entering the mass spectrometer, as they might
cause ion suppression [43]. As CSF samples contain proteins, they have to be
removed  prior  to  analysis  by  liquid  chromatography,  usually  by  protein
precipitation and centrifugation [32,67,74] or by ultrafiltration [25,75–77].
Concerning brain tissue samples,  the matrix is  much more complicated and
contains, for example, several different lipids, that might clog the analytical
HPLC  column  and  suppress  ionization  in  mass  spectrometry  (ESI) [55,78].
Neurotransmitters are often extracted from brain tissue by homogenization of
the sample and denaturing of proteins followed by analysis of the supernatant,
usually after centrifugation and/or filtration [79–82], liquid-liquid extraction
(LLE) [83], or solid-phase extraction (SPE) [84,85].
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1.2.4 LIQUID CHROMATOGRAPHY – MASS SPECTROMETRY
Liquid chromatography using reversed-phase (RP) columns, most commonly
C-18-columns, have previously been widely used [45,49,50,80–83,85–89]. Since the
monoamines are polar molecules with low molecular weights, they are poorly
retained  in  reversed  chromatography.  Ion-pair  agents  such  as  sodium octyl
sulfate are generally employed in the mobile phase in order to increase
retention  times  of  polar  analytes  such  as  DA  and  5-HT.  However,  these
additives are not volatile, and therefore not compatible with MS detection. The
phase II metabolites of the neurotransmitters are even more hydrophilic than
the unconjugated parent compounds, and therefore hydrophilic-interation
(HILIC) [42] or pentafluorophenyl-propyl columns have been utilized more
recently in the analysis of intact phase II metabolites [24,25,47,48].
Mass spectrometric (MS) methods have become more common in
neurotransmitter analysis, mostly coupled to high-pressure liquid
chromatography (HPLC) or ultra-high pressure chromatography (UHPLC),
utilizing atmospheric pressure ionization(API), usually electrospray (ESI)
which is most suitable for polar compounds (Table 1). Since neurotransmitters
are  present  in  the  brain  at  very  low  levels,  usually  triple  quadrupoles  in
selective reaction monitoring (SRM) mode have been used, either in positive
or negative mode [24,25,42,47,83,87]. Analysis of neurotransmitters by MS usually
does not require derivatization, but derivatisation with benzoyl chloride [45] or
deuterated acetaldehyde [90] has been used prior to analysis by LC-MS/MS to
improve sensitivity and selectivity. A major advantage of MS using ESI is that
the  analysis  of  intact  phase  II  conjugates  (glucuronide  and  sulfonate
conjugates) of neurotransmitters is possible [24,25,47].
1.2.5 OTHER DETECTORS
In addition to mass spectrometry, neurotransmitters are often analysed using
other  detectors,  such  as  ultraviolet  (UV),  electrochemical  (EC),  and
fluorimetric (FL) detection. As monoamine neurotransmitters are easily
oxidized, electrochemical (EC) detection has been widely used (Table 1) [46,49–
51,80,81,89]. EC detection is a form of voltammetry, and is based on the oxidation
(or  reduction)  of  the  analytes  in  the  mobile  phase.  EC  is  generally  more
sensitive than UV detection, and has thus been more widely used in
neurotransmitter analysis.
Also fluorometric detection is generally more sensitive than UV detection,
but often requires derivatization of the analyte with a fluorophore-containing
reagent. For DA fluorometric detection utilizing derivatisation with
diphenylethylenediamine has been proved more sensitive than UV detection
[86],  and  also  other  monoamine  neurotransmitters  have  been  analysed  with
fluorescence detection, usually after derivatization [62,63,88,91] or utilizing their
native fluorescence [82].
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1.3 ANALYSIS OF NEUROSTEROIDS
In contrast to the hydrophilic neurotransmitters, neurosteroids are lipophilic
compounds and have traditionally been analysed mostly by gas
chromatography – mass spectrometry (GC-MS). However, LC-MS techniques
have  also  become more  common in  neurosteroid  analysis  as  they  allow the
analysis of intact steroid conjugates. Additionally, steroids can be analysed by
UV detection, and also fluorescence detection after derivatisation has been
performed [96].
1.3.1 MATRIXES
As steroids are lipophilic compounds, microdialysis is not suitable for
sampling of neurosteroids, and therefore they are often analysed in CSF [97–
101]. The levels of neurosteroids in CSF have been shown to correlate with levels
in the brain [98]. Due to their lipophilic properties, neurosteroids can permeate
the  BBB,  and  therefore  analysis  in  matrixes  other  than  the  brain  is  also
possible. In addition to CSF, neurosteroids have often been analysed in plasma
[102–105].  Several  factors  affect  neurosteroid  levels,  such  as  stress,  sex,  and
health status.
Steroids  are  commonly  extracted  from  biological  matrixes  by  LLE
extraction using diethyl ether or dichloromethane as the organic phase, or SPE
extraction on a C-18 phase, or a combination of these [106,107]. As conjugated
steroids cannot be analysed by GC-MS, they are commonly hydrolyzed prior
to analysis enzymatically by the enzymatic extract from the snail H. Pomatia,
which contains both glucuronidase and sulfatase activity [108],  or  by  β-
glucuronidase derived from Escherichia coli [109], chemically [13,110], or directly
by derivatization, which causes simultaneous deconjugation [111].
1.3.2 GC-MS
Gas chromatographic analysis of steroids usually requires derivatisation to
improve the thermal stability and volatility of the analytes. After hydrolysis of
any conjugates, the remaining polar groups are commonly derivatised, mostly
by silylation to trimethylsilyl (TMS) conjugates prior to GC-MS analysis
[10,112]. Traditional GC-MS methods have utilized ionization in vacuum, such
as electron impact (EI) or chemical ionisation (CI). Electron ionization (EI),
which  is  commonly  used  in  the  GC-MS  analysis  of  steroids,  provides  high
sensitivity and reproducible spectra for all types of compounds, and it enables
the use of EI spectral libraries [101,113–115]. However, EI is an energetic
ionization  technique,  and  many  compounds  such  as  the  relatively  labile
derivatives of steroids are strongly fragmented and the formation of molecular
ions  is  weak.  CI  provides  less  energetic  ionization  for  steroids,  and  both
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positive CI [116,117] and negative CI [98,118,119] have been successfully used in the
analysis of steroids by GC-MS.
1.3.3 LC-MS
LC-MS is increasingly favored as it allows the analysis of intact steroids and
their conjugates without derivatization or hydrolysis of the conjugates [120]. All
the common atmospheric pressure ionization techniques, i.e., ESI [121,122],
atmospheric pressure chemical ionization (APCI) [123,124], and atmospheric
pressure photoionization (APPI) [125–127], have been applied in the analysis of
steroids by LC-MS. Since the ionization efficiency of ESI is relatively low for
nonpolar  steroids,  these  are  often  derivatized,  e.g.  with  hydroxylamine,  to
achieve sufficient sensitivity. On the other hand, ESI enables the analysis of
intact conjugates, such as glucuronides and sulfates [101,128]. APCI, and more
particularly APPI, provide better ionization efficiency than ESI for nonpolar
steroids, and high sensitivity can be achieved without the need for
derivatization. However, APCI and APPI are more energetic ionization
processes than ESI, and conjugates are usually cleaved during the ionization
[128,129].
Despite  the  advantages  of  LC-MS  techniques,  GC-MS  continues  to  be
widely used in the analysis of steroids, despite the need for derivatization and
hydrolysis. GC-MS is more robust than LC-MS, and although LC methods are
compatible with atmospheric pressure ionisation, the resolving power of GC
still  exceeds  that  of  LC,  giving  it  an  advantage  in  the  separation  of  steroid
isomers,  for  example.  Thus  the  coupling  of  GC  to  API  ionization  is  of  high
interest.
1.3.4 COUPLING GC TO API MASS SPECTROMETRY
As early as 1973, Horning et al. [130] interfaced GC to MS by using a 63Ni APCI
source. Later, APCI with a corona discharge needle [131], APPI [132–134], ESI
[135,136], and plasma ionization [137] have  been  successfully  used  in  the
interfacing of GC to MS. Commercially available GC-APCI-MS interfaces are
also available nowadays.  Our group has developed miniaturized APCI (μAPCI)
and APPI (μAPPI) GC-MS interfaces utilizing microfabricated, heated
nebulizer microchips and their potential in the analysis of steroids, polycyclic
aromatic hydrocarbons, amphetamines, polychlorinated biphenyls, and
selective androgen receptor modulators (SARMs) has been demonstrated
(Table 2) [138–141].   However,  the fabrication of  heated nebulizer microchips
requires advanced microfabrication technology and clean-room facilities, and
therefore we wanted to combine GC to MS via an APPI interface constructed
from simple commercially available hardware.
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Table 2. Examples of GC-MS methods using API ionization
Method Ionization Mass
spectrometer
Analytes Matrix Ref.
GC-MS/MS μAPPI QQQ Anabolic steroids Urine [141]
GC-MS/MS μAPPI QQQ PAH:s [138]
GC-MS/MS μAPPI/ μAPCI QQQ/orbitrap SARM:s Urine [140]
GC-MS/MS ESI QQQ MDMA, MDEA, others [135]
GC-MS ESI Q Volatile organic solvents [136]
GC-MS/MS μAPCI QQQ Anisole, benzaldehyde +others [142]
GC-MS APPI LIT-orbitrap Perfume sample [143]
GC-MS APCI TOF Metabolic fingerprinting Bacterialculture [144]
GC-MS APCI TOF Amino acids + others HumanCSF [145]
GC-MS MPPI TOF Caffeine, nicotine +others [146]
GCxGC-MS APCI TOF Flame retardants [147]
μAPPI/μAPCI=APPI  or  APCI  utilizing  a  nebulizer  microhip,  Q=single  quadrupole,  QQQ=  triple
quadrupole, TOF= time-of-flight mass spectrometer, GCxGC=two-dimensional GC, LIT=linear ion
trap
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2 AIMS OF THE STUDY
The aim of this work was to develop sensitive and specific mass spectrometric
methods  for  the  analysis  of  neurotransmitters  and  their  glucuronide  and
sulfate conjugates in microdialysis and cerebrospinal fluid samples.
Additionally,  a  quantitative  method  for  the  analysis  of  neurosteroids  in
biological samples was developed.
The more detailed aims were:
 to develop and validate a quantitative UPLC-MS/MS methods for the
analysis of human brain microdialysates and CSF samples (I)
 to  develop  an  UPLC-MS/MS  method  for  the  analysis  of  intact
neurotransmitter glucuronides and sulfates (I)
 to evaluate whether the sulfate conjugates of dopamine (DA-3- and DA-
4-S) are able to permeate the blood-brain barrier  (IV)
 to develop a sensitive and quantitative GC-MS/MS method for the
analysis  of  neurosteroids  by  coupling  of  GC  to  atmospheric  pressure
photoionization (II, III)
MATERIALS AND METHODS
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3 MATERIALS AND METHODS
3.1 CHEMICALS
All chemicals used in this study were analytical or chromatographic grade. The
structures of the compounds studied are shown in figures 1 and 2.
3.2 SAMPLES AND PRETREATMENT PROCEDURES
3.2.1 HUMAN BRAIN MICRODIALYSIS SAMPLES
Human brain  microdialysis  samples  (publication  I)  were  obtained  from the
Neurointensive care unit of the Uppsala University Hospital from two patients
with acute brain injuries (subarachnoid hemorrhage). Altogether 172 fractions
were  collected  from a  female  patient,  aged  71  years  (patient  1).  The  sample
volume was about 5-10 μL per fraction, collected in a time-resolved mode from
day  1-8.  The  other  patient  was  also  female,  aged  50  years  (patient  2);  132
fractions of  similar volume were collected from patient 2 in a time-resolved
mode from day 1-6. Both patients had a decreased level of consciousness, were
intubated and received artificial ventilation. Intracerebral microdialysis
sampling was initiated in conjunction with the insertion of an ICP monitoring
device through microdialysis catheters inserted via a bur hole placed 1–2 cm
anterior to the coronal suture.
Microdialysis catheters with a membrane length of 10 mm and a 20 kDa
nominal  molecular  weight  cut-off  polyamide  membrane  (70  Brain
Microdialysis Catheter; M Dialysis AB, Solna, Sweden) were used. The outflow
hydrostatic pressure of the perfusion system was set at the zero mid-cranial
reference  level  by  taping  the  collecting  vials  next  to  the  bandage  on  the
patient’s head. Perfusion of the catheters was performed using artificial CSF
(Perfusion  Fluid  CNS,  M  Dialysis  AB),  containing  NaCl  147  mM,  CaCl2  1.7
mM,  KCl  2.7  mM,  MgCl  0.85  mM,  total  chloride  contents  153.8  mM,
osmolarity  305  mOsm/kg),  delivered  at  a  rate  of  0.3  μL/min  by  using  a
microdialysis pump (106 MD Pump, M Dialysis AB). At least 2 hours passed
between  insertion  of  the  probe  and  the  start  of  sampling  to  allow  for
normalization of changes due to probe insertion. The samples were stored at -
70°C  until  the  analysis.  The  samples  were  injected  as  such  and  the
neurotransmitters and their glucuronide and sulfate conjugate contents were
measured.
The sampling was approved by the Regional Research Ethics Committee at
Uppsala  University,  and  a  written  informed consent  was  obtained  from the
patient or the patient's closest relative, in case the patient was unconscious.
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3.2.2 HUMAN CEREBROSPINAL FLUID SAMPLES
Human ventricular cerebrospinal fluid samples (publication I) were obtained
from the Department of Neurosurgery at Helsinki University Central Hospital.
The samples were obtained by ventriculostomy, and approximately 10 mL of
ventricular CSF was obtained from each patient. The patients were being
treated in the neurosurgical intensive care unit for obstructive hydrocephalus.
The patients were an 82-year old male with a cerebellar infarct (patient 3), a
46-year old female with subarachnoid hemorrhage (patient 4), a 35-year old
male  with  a  cerebellar  infarct  (patient  5),  and  a  55-year  old  female  with  a
tumor  (patient  6).  The  samples  were  taken  from  CSF  waste  accumulated
during therapeutic CSF drainage (appr. 200 ml/day/patient). Since the
samples were taken from CSF waste and were going to be discarded as a part
of the clinical routine, no informed consent from the patients or the next of kin
was deemed necessary.
A pool  of  CSF from 200 subjects,  all  without a neurologic or psychiatric
disease, most who underwent lumbar puncture for non-diagnostic reasons and
who  had  normal  CSF  clinical  laboratory  values,  was  obtained  from  the
Neurointensive care unit  at  the Uppsala University Hospital  (publication I).
Ages of  the patients ranged from 16 to 65 years with a median of  44 years;
50:50 female: male. These samples were collected on ice and cells were
removed  by  centrifugation.  Approval  for  the  conduct  of  this  study  was
obtained  from  the  local  Ethics  Committee  at  Uppsala  University  as  well  as
Göteborg University, Sweden. The participants provided their written
informed consent to participate in this study. A written informed consent was
obtained  from  the  next  of  kin,  caretaker,  or  guardian  on  the  behalf  of
participants that were not able to sign the informed consent themselves. The
ethics committees approved of this consent procedure.
All  CSF  samples  were  kept  at  -70  °C  until  analysis.   After  thawing,  the
samples were ultrafiltered by centrifugation (Millipore Amicon Ultrafree-MC,
30 000 NMWL : 12 000 g, 15 min), and the filtrate was injected as such. All
CSF samples were analyzed in triplicate.
3.2.3 RAT BRAIN MICRODIALYSIS SAMPLES
Rat brain microdialysis samples (publication IV) were obtained from Wistar
rats at 8-12 weeks of age. The rats were housed in groups of four to five per
cage and had free access to chow and water. They were maintained under a
12:12  h  light/dark  cycle  with  lights  on  from  06:00  to  18:00  at  an  ambient
temperature of 20-22 °C before the experiments.
The  animals  were  implanted  with  a  guide  cannula  (BAS  MD-2250,
Bioanalytical  Systems  Inc.,  IN)  using  a  stereotaxic  device  (Stoelting,  Wood
Dale, IL) under isoflurane anesthesia (4.5 % during induction for 5 min and
then 3.5 % during surgery). The guide cannula was aimed above the rat dorsal
striatum (A/P +1.0, L/M 2.7, D/V-6.0) according to the atlas by Paxinos and
Watson [148].  The  cannula  was  fastened  to  the  skull  with  dental  cement
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(Aqualox,  Voco,  Germany).  A  microdialysis  probe  (BAS  MD-2200,  2  mm
membrane, Bioanalytical Systems Inc., IN) was inserted into the striatum
through  the  guide  cannula  on  the  morning  of  the  experimental  day.  The
protocols  were  approved  by  the  National  Animal  Experiment  Board  of
Finland.
The collection of microdialysis samples with 30 min intervals (2.5 μL/min)
began 1  h after  insertion of  the probe.  Two baseline samples were collected
prior to the injection of a solution of 10 mM DA and 10 mM DA-S (containing
the  regioisomers  DA-3-S  and  DA-4-S)  at  a  volume  of  1  ml/kg  body  weight
(animals 1-3), or 10 mM 13DA-S (containing the regiosisomers 13DA-3-S and
13DA-4-S)  at  a  volume  of  1  ml/kg  body  weight  (animals  4-7).  After  the
injections microdialysis samples were collected for 3 hours. The microdialysis
samples were stored in a freezer (-70 °C) before analysis with UPLC-MS/MS.
The samples were injected as such without sample pretreatment.
3.2.4 HUMAN URINE SAMPLES
Human  urine  samples  (publications  II  and  III)  were  obtained  from  four
healthy volunteers (three females, one male). Each sample was divided into
three aliquots, for the analysis of free, glucuronidated, and sulfated
neurosteroids.  Free  neurosteroids  were  analyzed  by  adding  125  mg  of
NaHCO3/K2CO3 (2:1,  w/w)  to  2.5  mL of  urine  to  adjust  the  pH to  about  8.
Subsequently,  4  mL of  diethyl  ether  and  1.5  g  of  anhydrous  sodium sulfate
were added, the samples were centrifuged, and the organic layer was separated
and  evaporated  to  dryness.  Finally,  50  μL  of  derivatization  reagent
(MSTFA:NH4I:DTE,  1000:2:4,  v/w/w)  was  added,  and  the  samples  were
incubated at 60 °C for 15 minutes. The samples were injected into the GC as
such.
Glucuronide-conjugated neurosteroids were hydrolyzed by adding 1 mL of
0.8 M sodium phosphate buffer (pH 7) and 50 μL of β-glucuronidase from E.
coli. The samples were then incubated at 50 °C for 1.5 hours, cooled to room
temperature, and treated similarly to the free fraction samples. Sulfate
conjugates were hydrolyzed by adding 50 mg of L-cysteine and 500 μL of 6 M
HCl to the urine samples, which were incubated at 100 °C for 30 minutes. Then
275 μL of 10 M NaOH was added and, after cooling to room temperature, the
samples were treated in the same way as the free fraction. Methyltestosterone
was used as the internal standard in all samples.
3.2.5 SYNTHESIS OF REFERENCE COMPOUNDS
The phase II metabolites of 5-HT, DA, and their phase I metabolites (Table 3),
which  were  used  as  reference  standards  in  publications  I  and  IV,  had  been
synthesized earlier in our laboratory by methods described in detail elsewhere
[24,47,149].   Chemical  synthesis  of 13C6-dopamine-3- and 13C6-dopamine-4-
sulfates (13DA-3-S and 13DA-4-S) (publication IV) was performed by adding
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cold concentrated H2SO4 (200 μL)  to  20  mg  of 13C6-DA  HCl.  The  reaction
mixture was kept in ice for 20 minutes and then pipetted over 1 mL of frozen
water. The pH of the reaction mixture was adjusted to 3 with 5 M NaOH. The
sulfates were fractionated, evaporated to dryness under vacuum, lyophilized
and reconstituted in Ringer’s solution. The synthesis process is described in
more detail in publication IV.
3.2.6 UGT EXPERIMENTS
The glucuronidation activity of 19 human UGTs of subfamilies 1A, 2A, and 2B
were screened towards 5-HT and HVA (Publication I). All UGTs used had been
expressed in our laboratory as described earlier [150–152]. Glucuronidation
activities were determined with 2 mM 5-HT or HVA, and 5 mM UDPGA, 50
mM  phosphate  buffer  pH  7.4  and  10  mM  MgCl2, and the samples were
incubated at 37 °C for 60 min. All UGTs were screened as duplicates, except
for 5-HT as a substrate for 2B15, which was analyzed as a single sample and
showed no activity. Negative control samples, including all the reaction assay
components, with the exception of UDPGA, were also analyzed.
3.3 ANALYTICAL METHODS AND INSTRUMENTATION
3.3.1 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY
The  UPLC  used  for  the  analysis  of  microdialysis  and  CSF  samples  was  an
Aquity  UPLC  (Waters,  Milford,  MA).  The  column  used  was  a
pentafluorophenyl  column (Thermo Scientific  Gold  PFP Hypersil,  2.1  x  150
mm, 1.9 μm). Detailed conditions are listed in Table 3.
An Agilent 6410 triple-quadrupole mass spectrometer (Agilent
Technologies, Santa Clara, CA) equipped with an electrospray ion source was
used as the detector in all analyses. Nitrogen (Parker Balston N2-22 nitrogen
generator, Parker Hannifin Corporation, Haverhill) was used as the nebulizer
(40 psi), curtain (12 L/min, 350 °C), and collision gas. The fragmentor voltages
and collision energies were optimized for each compound, and Agilent
MassHunter software versions B.04.00 or B.06.00 (quantitative data analysis)
and B.03.01 or B.05.00 (qualitative data analysis) were used for data
acquisition and processing.
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Table 3. UPLC-MS/MS method for neurotansmitter analysis
Analyte SRM transitions Ionization UPLC settings
DA 154→137, 119, 91 ESI + UPLC: Waters Aquity
MS: Agilent 6410
Injection volume: 15μl
Flowrate: 300μl/min
time (min)      % org
0-1.5               3
1.5-12             15
12-13.2           65
13.5-25           3
DA-G 330→137, 154,91 ESI +
DA-S 232→152, 122 ESI -
HVA 181→137, 122 ESI -
HVA-G 357→193, 113, 175, 313 ESI -
HVA-S 261→217, 80 ESI -
DOPAC 167→123, 95 ESI -
DOPAC-G 343→299, 123, 113 ESI -
DOPAC-S 247→203, 123 ESI -
5-HT 177→160, 115, 132 ESI +
5-HT-G 353→160, 336, 177 ESI +
5-HT-S 257→240, 160, 115 ESI +
5-HIAA 190→146, 144, 116 ESI -
5-HIAA-G 366→146, 131, 113 ESI -
5-HIAA-S 270→226, 146, 80 ESI -
13C-DA-G 336→143, 160, 97 ESI + Neurotransmitter 13C-
metabolites
(publication IV)
13C-DA 160→143, 125, 97 ESI +
13C-DA-S 238→158, 128 ESI -
13C-DOPAC-G 349→305, 129, 113 ESI -
13C-DOPAC 173→129, 101 ESI -
13C-DOPAC-S 253→209, 129 ESI -
13C-HVA-G 363→193, 113, 175, 319 ESI -
13C-HVA-S 267→223, 80 ESI -
13C-HVA 187→143, 128 ESI -
3.3.2 GAS CHROMATOGRAPHY-MASS SPECTROMETRY
A HP 5890 II gas chromatograph (Hewlett–Packard, Waldbronn, Germany)
was used for the chromatographic separation of the neurosteroids both in the
GC-APPI-MS and the GC-CPI-MS setups. Two analytical columns, a TR-5MS
(length 25 m, i.d. 0.25 mm, 5% phenyl and 95% dimethyl polysiloxane, film
thickness 0.25 μm), and a TR-50MS (length 15 m, i.d. 0.25 mm, 50% phenyl
and  50%  methyl  polysiloxane,  film  thickness  0.25  μm),  both  from  Thermo
Fischer, were connected to each other with a press-fit connector (BGB Analytik
AG,  Boeckten,  Switzerland)  in  the  GC-APPI-MS  setup;  in  the  GC-CPI-MS
setup  a  BXP5  column  (length  15  m,  i.d.  0.25  mm,  from  SGE  Europe  Ltd.,
Milton Keynes, UK, was used). The more detailed analysis conditions are listed
in Table 4. A methyl-deactivated fused-silica precolumn (1.5 m×0.25 mm i.d.)
was connected in front of the analytical column, and a deactivated fused-silica
transfer capillary (ca. 1 m×0.15 mm i.d.) after the analytical column, both with
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press-fit connectors.  The carrier gas was 99.996% pure helium (AGA, Espoo,
Finland) with 150 kPa column pressure.
3.3.2.1 GC-APPI-MS interface
The fused-silica transfer capillary connected after the analytical column was
fed through a stainless steel (SS) T-piece placed inside the GC oven and then
through a SS capillary (i.d. 0.5 mm) acting as transfer line to the MS. The SS
transfer line was connected to the SS T-piece and heated to 330 oC with a self-
made  resistance  wire  heater.  Nitrogen  was  used  as  an  auxiliary  gas  at  80
mL/min. Chlorobenzene, used as dopant, was pumped with a syringe pump
(PHD 2000; Harvard Apparatus, Holliston, MA) at a flow rate of 3.5 μL/min,
vaporized,  and  mixed  with  the  nitrogen  flow.  The  nitrogen–dopant  gas
mixture was led through 1/16” o.d. SS tubing into the T-piece, and coaxially
through the heated transfer line to the APPI source. The tip of the fused silica
transfer  capillary  from  the  GC  was  positioned  with  a  zyx-manipulator
(Proxeon Biosystems A/S, Odense, Denmark) ca. 5-10 mm in front of the tip
of the MS extended capillary.
The Agilent 6410 triple-quadrupole mass spectrometer was also used as the
detector in this  study,  now utilizing APPI ionization.  The MS was equipped
with a commercial extended transfer capillary (KR Analytical Ltd., Sandbach,
UK). Nitrogen was used as curtain (12 L/min, 350 °C) and collision gas. The
fragmentor voltages and collision energies were optimized for each compound.
Ionizing  10  eV  photons  were  generated  by  a  krypton  rf  discharge  vacuum
ultraviolet  (VUV)  lamp  (PKR  100,  Heraeus  Noblelight  Analytics  Ltd.,
Cambridge, UK). SRM transitions and the GC temperature program are shown
in Table 4.
3.3.2.2 GC-CPI-MS
The CPI device consisted of a 1.5 mm i.d. stainless steel (SS) capillary (called
CPI capillary) with a 1 mm wide and 15 mm long opening, a flat SS plate with
a similar opening hard-soldered on the capillary, a 3 mm thick MgF2 window
(Thorlabs Sweden AB, Goteborg, Sweden), a top plate with an 18 mm circular
opening, and Teflon rings used as seals to hold the MgF2 window in place. The
capillary (bottom) side of the setup was painted with heat-resistant black paint
and  heated  with  IR  radiation  from  a  halogen  lamp  driven  by  a  DC  power
supply (ISO-TECH IPS2010, RS Components, Northants, U.K.). The injection
end of the CPI capillary was heated with a resistance wire heater, also driven
by a DC power supply (ISO-TECH IPS603, RS Components). An rf-excited 10
eV  (124  nm)  krypton  discharge  vacuum  ultraviolet  (VUV)  lamp  (PKR  100,
Heraeus  Noblelight  Analytics  Ltd.,  Cambridge,  U.K.)  was  used  to  initiate
photoionization.
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The  mass  spectrometer  in  the  CPI  experiments  was  an  Agilent  6330 ion
trap MS (Agilent Technologies, Santa Clara, CA) with a commercial capillary
extension (KR Analytical Ltd., Sandbach, U.K.). The CPI setup was connected
to the capillary extensionby inserting the extension a few millimeters into the
CPI capillary.
Table 4. GC-MS/MS method for neurosteroid analysis
Analyte SRM
transitions
Fragmentor
(V)
GC settings
DHEA 432→327, 237 180 GC: HP 5890 II
MS: Agilent 6410
Columns: TR-5MS (25m), TR-50MS (15m)
Injector: 250°C
Injection volume: 3 μl, splitless
Temperature program:
DT 434→405, 127 180
T * 432→301, 209 210
AN 430→234, 209 180
E1 414→309, 155 195
E2 * 416→285, 129 180
AP 462→195, 157 180
MT(istd) * 446→356, 301 180
IP 462→267, 157 180
PREG 460→265, 157 180 Isothermal 1 min 190°C
17-OHPREG 584→231, 230 185 12 °C/min 240°C
E3 504→386, 296 180 1 °C/min 255°C
5α-DHP 460→195, 157 180 12 °C/min 330°C
5α-THDOC * 550→243, 230 180 Isothermal 2.4 min 330°C
PROG * 458→353, 157 180
A 648→305, 233 180 Ionization: APPI
CS 630→435, 243 180 * APPI and CPI
11-DC 544→245, 147 180
CORT 634→349, 230 180
HC 632→234, 219 230
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4 RESULTS AND DISCUSSION
This chapter summarizes the results of this work; more detailed descriptions
can  be  found  in  publications  I-IV.  The  analysis  of  neurotransmitters  was
performed with a more traditional UPLC-MS/MS method, although the
microdialysis  sample  matrix  and  the  baseline  concentrations  of  the
neurotransmitters  required  a  very  sensitive  method  with  good
chromatographic separation. In addition to the many compounds included in
the analysis, Ringer’s solution contains high amounts of inorganic salts, which
had  to  be  separated  from  the  analytes  chromatographically  and  prevented
from reaching the mass spectrometer, as they cause ion suppression.
Concerning neurosteroid analysis, the focus was on developing a new interface
between GC and MS, making it possible to combine GC to MS by building an
interface for ionization at atmospheric pressure, but as also neurosteroids are
present in the brain at  low concentrations,  the developed method had to be
sensitive and selective.
4.1 ANALYSIS OF HUMAN BRAIN MICRODIALYSIS AND
HUMAN CSF SAMPLES
4.1.1 UPLC-MS/MS METHOD DEVELOPMENT
An UPLC-MS/MS method was developed for the analysis  of  DA, 5-HT, and
their phase I and phase II metabolites in human brain microdialysis and CSF
samples. The use of a pentafluorophenylpropyl column, instead of a commonly
used C-18 column, provided good retention and separation of the metabolites
from each other, and also from the inorganic salts in the Ringer’s solution. The
salts were directed to waste using column switching before the elution of the
analytes, in order to avoid contamination of the ion source.
The UPLC method provided high separation resolution for the analytes, as
well as for the regioisomers, DA-3-sulfate (DA-3-S) and DA-4-sulfate (DA-4-
S), in addition to HVA-O-glucuronide (HVA-O-G) and HVA-COO-glucuronide
(HVA-COO-G) (Figure 3). Electrospray ionization (ESI) in the positive ion
mode provided high ionization efficiency for 5-HT, DA, 5-HT-glucuronide (5-
HT-G), 5-HT-sulfate (5-HT-S), and DA-glucuronide (DA-G), whereas the
negative ion mode provided better ionization efficiency for DA-3-S and DA-4-
S,  as  well  as  for  DOPAC,  HVA,  5-HIAA,  and  their  glucuronide  and  sulfate
conjugates (Table 3) . The positive and negative ion ESI mass spectra showed
abundant [M+H]+ and [M–H]− ions, respectively, which were chosen as the
precursor ions. The identification of the neurotransmitters and their
metabolites was based on the comparison of the retention times and relative
abundances of 2-3 selected reaction monitoring (SRM) transitions (Table 3) of
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each analyte between the reference standards diluted in Ringer’s solution and
the authentic samples. The samples were analyzed in two runs using the same
chromatographic gradient but monitoring different SRM transitions in order
to maximize sensitivity and selectivity, Run 1 and Run 2 (Figure 3).
Figure 3 SRM ion chromatograms of the monoamine neurotransmitters and their
metabolites.
The UPLC-MS/MS method was validated for specificity, limit of detection
(LOD) with a signal-to-noise ratio (S/N) of 3, limit of quantification (LOQ)
with a S/N of at least 10 and at most a 20 % deviation from the linearity curve,
linearity, and repeatability, using standards diluted in Ringer’s solution (Table
5).  The  LODs  for  5-HT,  DA,  5-HT-G,  5-HT-S,  and  DA-G  analyzed  in  the
positive ion mode were 0.02-0.40 nM (0.3-6 fmol injected on the column).
The  LODs  for  DA-3-  and  DA-4-S,  HVA,  DOPAC,  5-HIAA,  and  their
glucuronides and sulfates in the negative ion mode varied between 0.3 and 25
nM (4.5-375 fmol injected on the column). The LODs for DA and 5-HT and
their metabolites were at the same level as described earlier [24,45,47,83,87]. With
the UPLC column (2.1  x  150 mm, 1.9 μm) an injection volume of  15 μL was
used in order to achieve sufficient sensitivity levels.
Concerning  the  microdialysis  samples,  the  recoveries  of  the
neurotransmitters  and  their  phase  I  and  II  metabolites  across  the
microdialysis membrane were not determined, but the typical in vivo recovery
for small molecules (glucose, lactate, pyruvate, glutamate) in microdialysis has
been reported to be 65-70% [153]. The concentration ratios between the
analytes  are  expected  to  be  similar  to  those  in  brain  fluid,  since  the
permeability of the analytes through the microdialysis membrane is not
selective.
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Table 5. Validation results for the neurotransmitters and their metabolites
Compound
Linearity
range
nM r2
LOD
S/N=3
nM
LOQ
S/N≥10
nM
Accuracy
%
Repeatability
10 nM, n=6
rsd %
100 nM, n=6
rsd %
DA 0.5-25 0.997 0.2 0.5 90-120 6.0 nm
DA-G 0.5-50 0.998 0.1 0.5 90-110 4.3 nm
DA-3-S 1-50 0.997 0.3 1 91-116 5.1 0.6
50-1000 0.998 93-115
DA-4-S 1-1000 0.998 0.3 1 91-112 5.7 1.5
5-HT 1-25 0.996 0.2 1 89-112 1.8 nm
5-HT-G 0.25-25 0.997 0.02 0.25 96-103 2.5 nm
5-HT-S 1-100 0.999 0.4 1 94-107 2.6 nm
DOPAC 50-1000 0.998 10 50 95-110 nm 4.7
DOPAC-G 25-1000 0.996 2.5 25 93-113 nm 2.0
DOPAC-S 25-1000 0.998 4.3 25 95-110 nm nm
HVA 100-1000 0.999 25 100 98-102 nm 7.0
250-5000  0.999 95-120
HVA-O-G 5-100 0.999 1.0 5 92-111 4.9 2.9
HVA-S 5-500 0.999 1.4 5 95-118 nm nm
5-HIAA 25-1000 0.998 6.4 25 91-106 nm 4.0
250-3500  0.999 95-103
5-HIAA-G 5-500 0.998 1.0 5 86-116 7.2 3.2
5-HIAA-S 10-1000 0.999 5.0 10 96-113 nm 10.0
nm= not measured
4.1.2 NEUROTRANSMITTERS AND THEIR METABOLITES IN HUMAN
BRAIN MICRODIALYSIS AND CSF SAMPLES
The human brain microdialysis samples from two patients (patients 1 and 2)
were analyzed as such. 5-HT was identified at low concentrations (< 1 nM) in
the microdialysis samples from patient 2, but not from patient 1. DA was not
detected in any of the samples. The most abundant metabolite of DA was HVA,
but  HVA-O-glucuronide  was  also  identified  in  the  samples  obtained  from
patient 1. DA-3-S was clearly identified in both patients, but DA-4-S was not
found in any of the samples. The most abundant metabolites of 5-HT were 5-
HIAA and 5-HIAA-S, but low concentrations of 5-HT-G were also identified in
the samples from patient 1 (Figure 4).
 Low concentrations of 5-HT (1.2 nM or less) were detected in three of the
ventricular  CSF  samples  similar  to  those  found  in  the  brain  microdialysis
samples. In comparison, DA was not detected in any of the samples. The most
abundant metabolite of DA was HVA, the concentrations of which were about
one order of magnitude higher in the ventricular samples than in the lumbar
sample. DA-3-S was detected in all the samples but DA-4-S only in one sample.
The most abundant metabolites of 5-HT were 5-HIAA and 5-HIAA-S, which
corresponded to those found in the brain microdialysis samples. 5-HT-S was
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detected at a low concentration only in the lumbar CSF sample, but 5-HT-G
that was detected in the microdialysis samples was not detected in any of the
CSF samples.
Figure 4 SRM ion chromatograms of A: a standard sample (1 nM 5-HT and 5-HT-G, 5 nM
DA-3-S and HVA-O-G, 100 nM HVA, 5-HIAA and 5-HIAA-S); B: a blank sample
(Ringer’s solution); C: a microdialysis sample from patient 1; D: a microdialysis
sample from patient 2.
The findings show that the main phase I metabolites of DA and 5-HT were
HVA and 5-HIAA, respectively. This is consistent with earlier studies of their
concentrations in human brain tissue [93,94,154–156] and human CSF samples
[65,93,95,157]. Earlier studies reported that DOPAC was detected in human brain
tissue samples [154–156,158], microdialysis samples [58,92],  and  CSF  samples
[65,93,95], but none was detected in this study. This may be due to insufficient
sensitivity  of  the  method  or  to  fast  degradation  of  DA  and  DOPAC  during
sample storage, as reported earlier by several groups [24,159,160].
The intact phase II metabolites, 5-HIAA-S, DA-3-S, DA-4-S, 5-HT-S, 5-HT-
G, and HVA-O-G were detected in human brain or CSF for the first time in this
work (Table 6). There are earlier reports of HVA-G, DOPAC-G, 5-HIAA-G, and
DOPAC-S in tissue samples of  the human brain [161],  and DA-G, 5-HT-G, 5-
HT- S [162], and DA- S [95,157,160,162–164] have been found in human CSF. All of
these metabolites were detected after a hydrolysis step, however, which makes
their determinations less reliable than our direct method of detecting intact
conjugates. In addition 5-HIAA-S, which has not been detected in the human
brain  or  CSF  in  earlier  studies,  was  now  found  at  relatively  high
concentrations. The concentrations of 5-HIAA-S were around 3-5 times higher
than  those  of  free  5-HIAA  in  the  human  microdialysis  and  lumbar  CSF
samples,  and about half  the concentration of  free 5-HIAA in the ventricular
CSF samples.
DA-3-S  was  clearly  detected  in  all  the  samples  and  DA-4-S  in  only  one
sample,  which  indicates  that  the  DA-3-S  regioisomer  predominates  in  the
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human brain.  These results  are in accordance with earlier  observations that
DA-3-S predominates in human plasma at concentrations of about ten-fold
higher than those of the regioisomer DA-4-S [165]. It has been shown that the
isoenzyme  SULT1A3,  which  is  also  found  in  the  human  brain[21], is
regioselective and strongly favors the formation of DA-3-S over DA-4-S [149].
Sulfonation of 5-HT was less favored than sulfonation of DA, as 5-HT-S was
only detected in the lumbar CSF sample at a low concentration.
The glucuronides 5-HT-G and HVA-O-G were detected for the first time in
human  brain  samples.  However,  the  glucuronides  were  only  found  in  the
microdialysis samples of patient 1 at low concentrations, and no glucuronides
were detected in the CSF samples. The amount of HVA-O-G was less than 1%
of the amount of free HVA. This result may be considered to be in line with the
reported 5-HT glucuronidation of UGT1A6 [166] and the barely detectable
expression of this enzyme in the brain [16,18].
Table 6. Findings in the human brain microdialysis and cerebrospinal fluid samples.
Microdialysis samples Cerebrospinal fluid samples
Patient 1 Patient 2 Ventricular Lumbar
Compound Sample
1
Sample
2
Sample
1
Sample
2
Patient
3
Patient
4
Patient
5
Patient
6
Pooled
5-HT - - 0.52a 0.54a 0.84a - 0.70a 1.2 -
5-HT-S - - - - - - - - 0.63a
5-HT-G 0.45 0.80 - - - - - - -
5-HIAA 90 110 90 100 1400 340 220 540 35
5-HIAA-S 450 550 520 380 370 170 96 390 86
5-HIAA-G - - - - - - - - -
DA - - - - - - - - -
DA-3-S 330 630 3.5 2.5 10 18 14 9.4 12
DA-4-S - - - - - - 2.0 - -
DA-G - - - - - - - - -
HVA 1100 2000 280 150 4200 600 2200 2200 120
HVA-S - - - - - - - - -
HVA-O-G 15 12 - - - - - - -
DOPAC - - - - - - - - -
DOPAC-S - - - - - - - - -
DOPAC-G - - - - - - - - -
The microdialysis samples (patients 1 and 2) were analyzed as singles. Each of the CSF samples
(four ventricular CSF samples (patients 1–4), one lumbar CSF sample pooled from several patients,
were analyzed in triplicate (concentrations shown are the mean concentrations). – not detected,
a<LOQ, concentration estimated by extrapolation of the linearity curve.
4.1.3 UGT SCREENING EXPERIMENTS FOR 5-HT AND HVA
Since  this  was  the  first  study  to  show  the  presence  of  intact  glucuronide
conjugates of 5-HT and HVA in a human brain sample, the glucuronidation
activity of 19 human UGTs of subfamilies 1A, 2A, and 2B were screened for 5-
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HT  and  HVA  in  order  to  evaluate  the  relevance  of  the  finding.  5-HT
glucuronidation has been previously well documented [16,166,167], but the
conjugation of HVA by recombinant UGTs is elusive. In this study, serotonin
was shown to be conjugated mainly by UGT1A6, but also by the UGTs 1A7-
1A10 in minor amounts. This was almost in agreement with previous results,
though low levels of UGT2B7 activity have also been observed for 5-HT [151].
HVA  can  be  glucuronidated  both  at  the  phenolic  hydroxyl  and  the
carboxylic acid group sites [24]. This screening experiment revealed that
UGT1A10  is  the  most  active  human  UGT  in  the  formation  of  HVA-O-
glucuronide, whereas UGT2A1 is the most active for the conjugation of HVA
at the –COOH-group (UGT screening experiment described in more detail in
publication I). The glucuronidation results showed that glucuronidation is not
a major biotransformation pathway for 5-HT and HVA in the human brain. In
general, the results suggest that conjugation with sulfonate is the major phase
II metabolism pathway in the human brain.
4.2 PERMEATION OF DOPAMINE SULFATE THROUGH
THE BLOOD-BRAIN BARRIER
Even though several sulfonate conjugates of neurotransmitters were detected
in  the  human  brain,  the  origin  of  these  was  not  studied.  It  is  not  known
whether the conjugates were locally formed in the brain, or whether they can
cross  the  BBB.  Therefore  the  BBB  permeation  of  DA  and  its  sulfonate
conjugates was studied by peripheral (subcutaneous) injections of DA, DA-3-
and DA-4-S, as well as 13C6-isotopically labeled DA-3-S (13DA-3-S) and DA-4-
S (13DA-4-S) in rats, while the concentrations of these compounds in the brain
were  simultaneously  monitored  by  microdialysis.  The  fate  of  the  injected
compounds, and their possible effects on the concentrations of DA, 5-HT and
their  metabolites,  were  studied  by  analyzing  the  rat  brain  microdialysis
samples using ultra-performance liquid chromatography-tandem mass
spectrometry (UPLC-MS/MS).
4.2.1 SYNTHESIS OF 13C-LABELED DOPAMINE SULFATE
The structures of the synthesized13DA-3- and 13DA-4-S were verified by UPLC-
MS  and  UPLC-MS/MS  using  negative  ion  mode.  The  ion  chromatograms
showed two peaks, the MS spectra of which showed abundant [M-H]- ions at
m/z 238 indicating the correct molecular weights of the synthetized 13DA-3-S
and 13DA-4-S.  The  product  ion  spectra  of  the  [M-H]-  showed  abundant
product ions [M-H-SO3]- (m/z  158)  and  minor  fragments  [M-H-CH2NH2]-
(m/z 128) and [SO3]- (m/z 80) (Figure 5). Based on UV detection, the mixture
of the 13DA-S regioisomers contained 53% of 13DA-4-S and 47% of 13DA-3-S.
The  sulfation  sites  were  verified  by  NMR.  The  spectra  of  the  DA-S
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regioisomers  are  in  accordance  with  earlier  reported  NMR  data [149]
confirming sulfonation to the hydroxyl groups attached to carbons 3 and 4.
Figure 5 Extracted ion chromatogram, MS and MS/MS spectra (negative ion mode) of the
synthesized 13DA-S.
4.2.2 BBB PERMEATION EXPERIMENT
A mixture containing DA-S (DA-3-S and DA-4-S, 1:1) 2.3 mg/kg and DA 1.5
mg/kg was injected subcutaneously (s.c) and the concentrations in rat brain
were followed by microdialysis. Microdialysis samples were collected at 30
minutes intervals for 3 hours after administration (n=3, Rats 1-3). By also
injecting intact  DA, the function of  the BBB was controlled,  as DA does not
permeate the BBB. In all three rats the concentrations of DA-3-S and DA-4-S
were below the limit of detection before the injection, but increased clearly 30
min after the injection (Figure 6). To confirm the results, the experiment was
repeated with a mixture of labelled 13DA-S regioisomers (2.4 mg/kg) (n=4,
Rats 4-7). Again, in all four rats, the concentrations of both 13DA-3-S and 13DA-
4-S increased clearly 30 min after the s.c. injection. In contrast to DA-S, the
concentrations of intact DA did not change significantly after the injection,
measuring at  the same levels  as reported earlier  in rat  striatal  microdialysis
samples (0.7-8 nM) [24,47,49]. These results clearly show that DA-S permeates
the intact BBB.
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Figure 6 Concentrations of non-labeled and 13C6-labelled DA-3-S and DA-4-S in rat brain
microdialysates after s.c. injections.
4.2.3 EFFECT OF THE INJECTED DA-S ON THE CONCENTRATIONS
OF OTHER NEUROTRANSMITTERS IN THE BRAIN
As  the  pharmacological  properties  of  DA-S  are  are  unknown,  despite  some
reported properties such as convulsions after intraventricular injections
[168,169], the  concentration  profiles  of  the  other  naturally  occurring
neurotransmitters,  non-labelled  DA,  5-HT,  and  their  metabolites  (Table  3),
were studied in microdialysis samples collected before, during, and after the
injection of 13C6-labelled DA-S. The basal concentrations of the naturally
occurring analytes measured before the injections were in accordance with
earlier  published  values  for  rat  brain  microdialysis  samples  collected  from
freely moving rats [24,47,50,88], even though this experiment was performed
with anesthetized rats.
The concentrations of the naturally occurring non-labelled metabolites of
dopamine  (DA-G,  DOPAC,  DOPAC-S,  HVA and HVA-S)  increased  after  the
injections of 13C6-labelled DA-S, while no clear trend in the levels of DA could
be observed. 5-HT and its metabolites followed a similar trend: while the 5-
HT levels decreased in all animals during the experiment, the concentrations
of  its  metabolites  (5-HT-G,  5-HIAA  and  5-HIAA-S)  increased  during  the
experiment (Figure 7). The injected 13DA-S may affect the metabolism process
of naturally occurring dopamine and/or other neurotransmitters, but
anesthesia itself might also have an impact on the concentration changes. The
influence of volatile anesthetics on neurotransmitter levels have been reported
earlier:  isoflurane  has  been  shown  to  lower  5-HT  levels  in  rats  and  mice
compared to levels during wakefulness [170,171]. Isoflurane anesthesia has also
been  shown  to  increase  DA  levels  at  high  doses  (3%  isoflurane),  while  the
levels of DOPAC and HVA increased at all isoflurane concentrations studied
[172,173]. Similar effects have been reported for halothane and sevoflurane
[174,175].  Based  on  the  literature  it  seems  likely  that  the  fluctuations  in
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neurotransmitter levels are due to anesthesia. Moreover, the isoflurane
concentrations had to be slightly adjusted during the experiments, which
might have additionally influenced the neurotransmitter levels. However, this
does not rule out that the injected DA-S might also have contributed to these
level changes.
Figure 7 Concentrations of the neurotransmitters (Left: dopamine metabolites, right:
serotonin metabolites) during the test in rat brain microdialysates in one of the test
animals.
4.3 DEVELOPMENT OF A GAS CHROMATOGRAPHIC –
TANDEM MASS SPECTROMETRIC ANALYSIS
METHOD FOR NEUROSTEROIDS USING
ATMOSPHERIC PRESSURE PHOTOIONIZATION
Miniaturized APPI (μAPPI) GC-MS interfaces utilizing microfabricated,
heated nebulizer microchips  have been successfully used  in the analysis of
steroids [141,176]. In this work we combined GC to MS via a new APPI interface
constructed from simple commercially available hardware. The feasibility of
the  method  was  demonstrated  in  the  analysis  of  trimethylsilylated  (TMS)
neurosteroids in human urine samples. The interface was further modified to
a capillary photoionization interface (CPI), in which ionization takes place
inside  a  heated  transfer  capillary  between  the  GC  and  the  MS  inlet,  thus
maximizing ion transmission.
4.3.1 CHROMATOGRAPHIC SEPARATION
High  chromatographic  separation  power  is  essential  in  the  GC-MS/MS
analysis of steroids to separate the numerous isobaric and isomeric forms. The
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separation of co-eluting isobaric and isomeric steroids is often impossible by
MS/MS,  since  fragmentation  behavior  may  be  similar,  and  specific  product
ions are not necessarily formed. Furthermore, M+1 and M+2 isotopes and
fragments of trimethylsilyl-derivatized steroids may disturb the analysis. In
our GC-MS/MS method,  the use of  two different GC columns (TR-5MS and
TR-50MS) connected in tandem provided high chromatographic resolution
and sufficient analytical specificity (Figure 8).
The  hydroxyl  and  keto  groups  of  the  steroids  were  converted  into
trimethylsilyl (TMS) ethers and enol ethers following previously described
procedures [177,178]. The chromatographic separation of the compounds had to
be optimized carefully, since several of the neurosteroids eluted as two
chromatographically separated isomeric peaks. This was due to an acetyl
group at position 17 (PROG, PREG, 5α-DHP, IP, AP and 17-OH-PREG) or a
hydroxyacetone  group  in  the  same position  (5α-THDOC and A),  the  ketone
group of which may form an enol to either side of the double bond (Z- and E-
isomers) during derivatization, with resultant elution of two chromatographic
peaks [113]. Aldosterone (A) additionally has an aldehyde group at position 13,
which is not derivatized owing to the formation of the hemiacetal isomer [179].
Figure 8 SRM chromatograms of the neurosteroids.
4.3.2 POSITIONING OF THE GC TRANSFER LINE AND KRYPTON
DISCHARGE LAMP
As the interface between GC and MS was self-built and a the ionization region
was  completely  open,  the  GC  transfer  line  and  the  VUV  lamp  had  to  be
arranged carefully  in order to maximize ion transmission into the MS.  The
positions  of  the  tip  of  the  heated  transfer  line  from  the  GC,  which  was
positioned  with  a  zyx-manipulator,  and  the  krypton  discharge  vacuum  UV
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(VUV) lamp in relation to the extended capillary of the MS inlet were crucial
in achieving maximum sensitivity. The optimal position for the end of the GC
transfer line was 5 to 10 mm from the tip of the extended capillary. Stability of
the signal was best when the flow from the GC was directed toward the tip of
the  extended  capillary  at  an  angle  of  about  45°  (Figure  9).  The  lamp  was
positioned as close as possible (about 2 mm) to the sample plume generated
at  the  end  of  the  transfer  line.  A  longer  distance  between  the  UV lamp and
plume allowed absorption  of  the  photons  by  air,  decreasing  the  intensity  of
radiation  at  the  plume  and  the  ionization  efficiency.  The  flow  rates  of  the
dopant and the auxiliary gas (used for dopant vaporization) were optimized,
and optimal sensitivity and stability were achieved with dopant and auxiliary
gas flow rates of 3.5 μL/min and 80 mL/min, respectively.
Figure 9 Schematic (right) of the GC-APPI-MS/MS connection setup and picture (left)
showing the MS inlet. Reprinted from [180] with permission from Elsevier.
4.3.3 DOPANTS
The effects of several dopants (chlorobenzene, toluene and anisole) on
ionization of  the TMS (Si(CH3)3) derivatives of the steroids were compared.
With  all  dopants  and  for  most  TMS-steroids,  the  APPI-MS  spectra  showed
abundant  molecular  ions  (M•+),  formed  via  charge  exchange  reaction,  with
minimal fragmentation. When chlorobenzene was used as dopant, the TMS-
steroids produced no or only minor amounts of protonated molecules
([M+H]+),  as  shown  by  the  same  or  only  slightly  higher  proportions  of  the
[M+1] peaks relative to the theoretical isotopic abundances. The use of toluene
or anisole, however, resulted in the formation of [M+H]+, as seen in the higher
relative abundances of [M+1] peaks  than with chlorobenzene (Figure 10). The
ionization  energy  of  chlorobenzene  (9.07  eV)  is  higher  than  that  of  toluene
(8.82 eV) or anisole (8.20 eV)[181], which favors charge exchange reactions and
the formation of M•+ ions.  Many unknown factors,  such as the formation of
cluster ions and gas phase reactions with the dopant,  could,  however,  affect
the  reactant  ion  composition  and  thus  the  ionization  process.  Because
chlorobenzene provided good ionization efficiency and a more uniform
ionization process than toluene or anisole,  it  was selected as the dopant for
further experiments.
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Under similar experimental conditions, nonderivatized steroids have been
demonstrated to produce abundant [M+H]+ rather  than  M•+ ions [141]. The
probable explanation for the different results is  that increase in molecular size
through TMS derivatization of the hydroxyl and keto groups tends to decrease
the ionization energy of the steroids [182,183]. The trimethylsilyl groups also
lower the proton affinity of the analytes by binding to the possible protonation
sites. Moreover, the TMS group causes steric hindrance for the proton transfer
to the ether oxygen.  Thus, the TMS derivatives of the studied steroids are more
likely ionized by charge exchange than by proton transfer reaction.
Figure 10 Spectral peak distribution of testosterone with A) chlorobenzene, B) toluene and C)
anisole as dopant. Reprinted from [180], with permission from Elsevier.
4.3.4 MASS SPECTROMETRY
The  MS  spectra  of  almost  all  the  TMS-derivatized  steroids  measured  with
chlorobenzene as dopant showed an M•+ ion as the main peak. Exceptionally,
corticosteroids, which have a hydroxyacetone side chain and a hydroxyl group
at position 17 (11-DC, CS and HC), showed a [M-TMS-H2O]+ fragment ion as
the  main  peak  and,  additionally,  a  minor  fragment  ion  [M-Si(CH3)2]+. This
indicates  that  when  a  hydroxyacetone  side  chain  is  present  at  position  17,
TMS-derivatives of the hydroxyl group at position 17 are less stable than the
other  TMS-derivatized  groups.  Those  steroids  with  a  hydroxyacetone  side
chain but no hydroxyl group at position 17 show a single peak of (M•+) in their
spectra. For most of the compounds, the fragmentation was low, and most of
the fragments, such as [M-TMS]+, [M-Si(CH3)2]+, and [M–CH3]+, were formed
through dissociation of the TMS group.
M•+ was selected as the precursor ion for all analytes except 11-DC, CS, and
HC, for which [M-TMS-H2O]•+ was selected, and A, for which [M-TMS]•+ was
selected.  In  addition  to  abundant  nonselective  ions  formed by  the  loss  of  a
methyl group or the loss of TMS and water, the MS/MS spectra also showed
numerous and abundant specific fragment ions formed by the dissociation of
the ring structure of the steroid. The fragmentation follows the odd-electron
fragmentation pathway, and therefore the product ion spectra of the TMS-
derivatized steroids are closely similar to the corresponding EI spectra (Figure
11), and EI libraries could thus be utilized in the identification of unknown
compounds.
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Figure 11 GC-APPI-MS/MS and GC-EI spectra of DHEA. The EI spectra was measured with
an Agilent 6890N GC connected to an Agilent 5975B MSD mass spectrometer
using an electron energy of 70 eV.
4.3.5 VALIDATION OF THE METHOD AND ANALYSIS OF URINE
SAMPLES
Spiked artificial urine samples were used for method validation.  The steroids
were extracted from the urine samples with diethyl ether as described
previously [184,185]. The validated parameters were linearity, limits of detection
and quantification (LOD and LOQ), repeatability, and liquid–liquid extraction
(LLE) recovery. For linearity measurements, the artificial urine samples were
spiked with the analytes at concentrations from 0.25 pg/mL to 5000 ng/mL.
The LLE recovery was measured by comparing two artificial  urine samples,
one spiked with standards at 10 ng/mL before LLE and one spiked at the same
level after LLE (triplicate samples). The extraction recoveries varied between
43  and  87%,  which  is  adequate,  as  the  repeatability  of  the  method  was
acceptable with relative standard deviations better than 22%.
The  LODs  were  0.1-0.2  ng/mL for progestagens (PREG, PROG, 17-OH-
PREG), 0.02-0.1 ng/mL for estrogens (E1, E2, E3), 0.02-0.1 ng/mL for
androgens (DHEA, AN, T, DHT), 0.75-1.0 ng/mL for glucocorticoids (11-DC,
HC, CS), and 0.2-10 ng/mL for mineralocorticoids (A, CORT). LODs reported
in  the  literature  for  GC-EI/MS  are  in  the  range  of  0.06-3  ng/mL for
progestagens [105,113,186], 0.08-0.16 ng/mL for estrogens [105], 0.06-2.5 ng/mL
for androgens [105,113,114,186], and 0.07 ng/mL for corticosteroids [113]. The
sensitivity of our method is thus well comparable with sensitivities presented
in  the  literature.  The  within-day  repeatability  of  the  method  was  studied  at
concentration  levels  of  20  and  50  ng/mL,  by  spiking  analytes  into  artificial
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urine (six replicates). The relative standard deviations (% rsd) were below 15%,
indicating good repeatability. The results are shown in Table 7.
The performance of the GC-APPI-MS/MS-method was verified by
analyzing human urine samples.  Each sample was divided into three aliquots:
one  used  for  the  analysis  of  the  free  fraction  of  steroids,  one  analyzed  after
enzymatic hydrolysis of glucuronides with β-glucuronidase, and one analyzed
after  acid  hydrolysis  of  sulfates.  The  steroids  were  detected  mostly  as
conjugates (Table 8). The results agree well with an earlier study [187], in which
3α-hydroxysteroids (such as AP and 5α-THDOC) were show to be conjugated
mainly with glucuronic acid; 3β-hydroxysteroids (such as PREG and DHEA)
conjugated with sulfate; and 17β-hydroxysteroids (T, E2, E3 and DHT) could
be conjugated with both glucuronic acid and sulfate. In addition to PREG and
DHEA, which were excreted as sulfate conjugates, AN was mostly, and CORT
completely, excreted in this form. The corticosteroids CS and HC, which are
slightly less lipophilic than androstanes and pregnanes, were the only steroids
detected  in  an  unconjugated  form in  all  samples.  This  finding  is  consistent
with earlier results [188].
Table 7. Validation results for the neurosteroids
Compound
Linearity
ng/ml r2
LOD
S/N=3-5
ng/mL
LOQ
S/N ≥10
ng/mL
Repeatability, n=6 LLE
extraction
recovery %20ng/mLrsd %
50ng/mL
rsd %
11-DC 1-100 0.992 0.75 1.0 8.9 4.1 87
17-OHPREG 1-100 0.997 0.1 1.0 8.4 6.5 61
5α-DHP 10-500 0.996 5.0 10.0 5.0 22.4 53
5α-THDOC 0.5-10 0.999 0.01 0.5 12.7 10.0 63
A 100-2500 0.990 10.0 100.0 1.1 1.5 85
AP 2-100 0.997 0.2 2.0 7.3 3.6 50
AN 0.2-10 0.999 0.02 0.2 2.6 2.9 67
CORT 2-50 0.994 0.2 2.0 2.3 1.1 61
CS 5-250 0.994 1.0 5.0 3.1 2.1 57
DHEA 2-100 0.996 0.2 0.75 9.8 11.6 69
DHT 0.5-20 0.998 0.1 0.2 13.1 3.7 70
E2 0.2-10 0.993 0.1 0.2 13.7 4.8 66
E3 0.5-10 0.998 0.02 0.5 15.0 6.2 70
E1 0.5-5 0.994 0.05 0.5 14.2 6.8 58
HC 2-100 0.995 0.75 2.0 2.0 4.8 69
IP 1-100 0.994 0.75 1.0 7.6 6.3 43
PREG 1-50 0.998 0.2 1.0 2.9 3.3 53
PROG 0.5-10 0.994 0.1 0.5 5.8 6.0 55
T 0.2-10 0.997 0.1 0.2 11.9 3.0 70
T 5-250 0.997
47
Ta
bl
e 
8.
C
on
ce
nt
ra
tio
ns
 (n
g/
m
L)
 o
f t
he
 s
te
ro
id
s 
in
 u
rin
e 
sa
m
pl
es
 fr
om
 th
re
e 
fe
m
al
es
 a
nd
 o
ne
 m
al
e.
  T
he
 s
am
pl
es
 w
er
e 
an
al
yz
ed
 in
 d
up
lic
at
e 
an
d 
av
er
ag
e
va
lu
es
 a
re
 p
re
se
nt
ed
.
Fr
ee
11
-D
C
 
17
-O
H
- 
5α
- 
5α
-
A
A
P
A
N
 
 
C
O
R
T 
C
S
D
H
EA
 
D
H
T 
E2
E3
 
E1
H
C
 
IP
PR
EG
 
PR
O
G
 
T
fr
ac
tio
n
PR
EG
 
D
H
P
TH
D
O
C
Fe
m
al
e 
1
-
-
-
-
-
-
-
-
16
.7
 
-
-
-
-
-
10
.1
 
-
2.
7
-
-
Fe
m
al
e 
2
-
-
-
-
-
-
-
-
43
.1
 
-
-
-
-
-
33
.5
 
-
-
-
-
Fe
m
al
e 
3
-
-
-
-
-
-
-
-
46
.9
 
-
-
-
-
-
26
.1
 
-
-
-
-
M
al
e 
1
-
-
-
-
-
-
1.
4
 -
74
.9
 
-
-
-
-
-
86
.6
 
-
-
-
0.
3
G
lu
cu
ro
ni
de
 
11
-D
C
 
17
-O
H
- 
5α
- 
5α
-
A
A
P
A
N
 
 
C
O
R
T 
C
S
D
H
EA
 
D
H
T 
E2
E3
 
E1
H
C
 
IP
PR
EG
 
PR
O
G
 
T
fr
ac
tio
n
PR
EG
 
D
H
P
TH
D
O
C
Fe
m
al
e 
1
-
-
-
1.
0
-
20
.2
 
0.
6 
-
23
.5
 
6.
4
1.
4 
0.
2 
1.
0 
1.
5 
15
.7
 
-
2.
3
-
-
Fe
m
al
e 
2
-
-
-
1.
4
-
24
.6
 
-
-
85
.5
 
20
.6
 
0.
9 
0.
4 
2.
0 
2.
2 
51
.0
 
-
-
-
2.
5
Fe
m
al
e 
3
-
-
-
1.
3
-
29
.2
 
1.
0 
-
70
.1
 
7.
9
0.
6 
0.
5 
2.
4 
3.
2 
31
.0
 
-
1.
0
-
1.
6
M
al
e 
1
-
2.
7
-
3.
7
-
33
.2
 
2.
5 
-
13
4.
8 
41
.3
 
3.
6 
1.
2 
5.
0 
5.
8 
73
.7
 
-
-
-
38
.7
Su
lfa
te
11
-D
C
 
17
-O
H
- 
5α
- 
5α
-
A
A
P
A
N
 
 
C
O
R
T 
C
S
D
H
EA
 
D
H
T 
E2
E3
 
E1
H
C
 
IP
PR
EG
 
PR
O
G
 
T
fr
ac
tio
n
PR
EG
 
D
H
P
TH
D
O
C
Fe
m
al
e 
1
-
-*
-
-
-
38
.4
 
5.
3 
5.
3
-
12
.6
 
0.
5
0.
04
* 
-*
0.
6*
-
-
2.
7*
-
1.
1
Fe
m
al
e 
2
-
-*
-
-
-
64
.3
 
19
.1
 
5.
3
21
.6
 
21
2.
1 
0.
2
0.
17
* 
0.
7*
 
0.
8*
22
.4
 
-
11
.7
*
1.
9
3.
7
Fe
m
al
e 
3
-
-*
-
-
-
44
.5
 
7.
1 
4.
5
15
.3
 
19
2.
7 
0.
2
0.
1*
 
-*
1.
2*
-
-
11
.3
*
-
1.
3
M
al
e 
1
-
-*
-
-
-
12
2.
7 
22
.2
 
7.
0
37
.4
 
42
6.
7 
1.
0
0.
3*
 
1.
9*
 
1.
5*
24
.1
 
-
47
.5
*
2.
1
30
.7
* 
th
es
e 
co
m
po
un
ds
 w
er
e 
si
gn
ifi
ca
nt
ly
 d
ec
om
po
se
d 
un
de
r 
th
e 
ac
id
 h
yd
ro
ly
si
s 
co
nd
it
io
ns
 a
nd
 th
e 
re
su
lts
 m
ay
 n
ot
 r
ef
le
ct
 a
ct
ua
l l
ev
el
s 
in
 th
e 
sa
m
pl
es
RESULTS AND DISCUSSION
48
4.3.6 CAPILLARY PHOTOIONIZATION
The  developed  APPI  interface  for  GC-MS  showed  good  potential  for  the
analysis  of  steroids,  but  the  interface  was  still  a  self-made  prototype  with  a
completely open ionization region. Ionization efficiency and ion transmission
are the key factors affecting the sensitivity of mass spectrometric analysis
utilizing atmospheric pressure ionization (API).  When analytes are ionized at
atmospheric  pressure,  most  of  the  ions  are  lost  when  transferred  to  the
vacuum of the mass spectrometer [189,190], and as the ionization region in the
GC-APPI-MS/MS setup was completely open, a more shielded interface was
constructed. Earlier photoionization for generating ions inside a transfer
capillary  between  the  atmosphere  and  the  vacuum  of  the  MS  has  been
performed  using  a  miniature  spark  discharge  VUV  lamp  embedded  in  a
transfer capillary with a windowless aperture (cAPPI) [191].
A high sensitivity ionization method, in which ionization takes place inside
a capillary, called capillary photoionization (CPI), was constructed. In the GC-
CPI-MS  setup,  the  tip  of  the  SS  tubing  from  the  GC  was  inserted  a  few
millimeters  into  the  CPI  capillary.  The  CPI  capillary  was  connected  to  the
extended  capillary  of  the  MS  by  inserting  the  extended  capillary  a  few
millimeters  into  the  CPI  capillary  (Figure  12).   The  sample  was  introduced
(injected manually, or from the GC) into the transfer capillary and vaporized
by  heat.  VUV  radiation  entered  the  capillary  through  the  VUV-transparent
MgF2 –window, and ionized the analytes by photoionization. With this CPI-
setup, non-volatile and liquid samples can also be ionized.
The sensitivity of CPI-MS was first tested by direct injections. Samples of 2
μL were injected manually, with a 10 μL syringe, about 5 mm inside the heated
capillary.  Injection  speed  was  about  1  μL/s.  In  MS/MS  mode  the  LOD  for
testosterone was at low fmol level.
Figure 12 Schematic of the capillary photoionization device connecting GC to an API mass
spectrometer. Adapted from [192], with permission from Elsevier.
The  performance  of  GC−CPI-MS/MS  was  further  tested  with  TMS-
derivatized steroids (T, PREG, PROG, E2 and THDOC). As in the GC-APPI-
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MS setup, with chlorobenzene as dopant, the TMS-steroids produced intense
molecular  ions  (M+•)  via  charge  exchange  reaction,  with  no  formation  of
protonated  molecules  and  minimal  fragmentation.  No  peak  broadening  or
tailing  was  caused  by  the  CPI  interface,  due  to  the  high  temperature  of  the
setup.
Artificial urine samples spiked with steroids (T, PROG, PREG, E2, and
THDOC) were used for the validation of the GC-CPI-MS method. The sample
pretreatment was similar to the GC-APPI-MS/MS method. The validated
parameters  were  linearity,  limits  of  detection  (LOD),  and  injection
repeatability. The application was verified by analyzing human urine samples
from two healthy males. The LODs (with a S/N of 3) for the steroids spiked in
artificial  urine  were  between  2  and  6  pg/mL,  being  lower  or  equal  to  those
presented for GC-EI-MS/MS [105,113]. Repeatability of injection with GC-CPI-
MS/MS was good: RSDs of the peak areas were 7% or less at a concentration
of  5  ng/mL.  The  linearity  of  the  method  was  measured  in  the  range  of  10
pg/mL to 100 ng/mL, and the coefficient of determination (r2) was higher than
0.993, indicating good linearity.
As  the  CPI-device  is  heated,  and  can  also  handle  liquid  samples  and
nonvolatile compounds, it can be used both for direct liquid injection and for
connecting LC to MS. CPI also enables GC instruments to be used with API
mass  spectrometers  intended  for  LC-MS.  The  initial  results  indicated  high
sensitivity, thanks to the high iontransmission efficiency. The results from the
analysis of selected steroids in urine samples show that the method has good
potential for being used in applications of analyzing less polar compounds
such as steroids in biological samples. Further experiments with GC, LC, and
other types of mass spectrometers are needed to demonstrate the full potential
of CPI.
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5 SUMMARY AND CONCLUSIONS
The microdialyis sampling and the developed UPLC-MS/MS-analysis method
require minimal sample pretreatment, and provide sensitive and selective
analysis  of  intact  phase  II  metabolites  of  neurotransmitters  in  the  human
brain. In this study, intact phase II metabolites of 5-HT and DA were analyzed
in human brain samples without hydrolysis of the conjugates, and several
intact glucuronides and sulfates were unambiguously identified and
quantified in human brain microdialysis and CSF samples for the first time. 5-
HIAA-S was also determined for the first time in human brain. As the direct
method provides analysis of regioisomers of conjugates, we were able to show
that DA-3-S predominates over DA-4-S in the human brain. The results show
that sulfonation is a more important phase II metabolism pathway than
glucuronidation in the human brain. Further studies, including samples from
a larger group of patients, are still required to study interindividual differences
in the amounts of conjugated neurotransmitters versus the concentrations of
the parent compounds.
The  role  and  the  origin  of  the  conjugated  neurotransmitter  in  the  brain
remains  unknown.  It  is  also  unknown  whether  the  conjugates  possess
neurotoxic or neuroprotective properties, if they are pharmacologically active
or not, and additional experiments are needed to study the pharmacological
impact of conjugated and especially sulfonated neurotransmitters on different
brain  functions.  DA-S  is  assumed  to  be  biologically  less  active  than  DA,
possibly providing a source for free DA in brain through enzymatic hydrolysis.
Therefore, the study of the permeation of DA-S through the human BBB and
the fate of DA-S in human brain is of great interest.
The peripheral injections of 13C-labelled DA-S followed by analysis of brain
microdialysis samples by UPLC-MS/MS provides a reliable method to study
the permeation of DA-S through the BBB. The study clearly shows that DA-S,
but not DA, is able to permeate the BBB of rats. The result is interesting, since
DA-S is more polar than DA, and the passive permeation of DA-S through the
BBB  is  not  obvious.  Therefore,  it  can  be  concluded  that  DA-S  most  likely
permeates the BBB by binding to an active transporter-protein located in the
BBB.  However,  it  is  unknown  which  transporter  protein  is  responsible  for
transporting DA-S through the BBB into the brain,  which will  be a focus of
future studies.
Even though the results show that DA-S crosses the BBB, no information
on  the  fate  of  the  permeated  DA-S  in  the  brain  was  acquired.  The  results
showed that DA-S is not hydrolyzed to DA or transformed into any common
metabolites of DA with concentrations above the limits of detection of this
method.  It  is  therefore  possible  that  DA-S  is  metabolized  by  an  unknown
mechanism, or is transported out of the brain by active transporters. However,
these results obtained from experiments with rats cannot be directly applied
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to humans. DA-S has been found in human brain microdialysis samples
previously [25], but not in rat brain microdialysis samples, indicating that the
concentration of DA-S in human brain is significantly higher than in rat brain.
Steroids  have  recently  been  analyzed  by  methods  combining  gas
chromatography (GC) to atmospheric pressure photoionization utilizing
heated nebulizer microchips (μAPPI). The interface constructed in this work
for  combining  GC  to  mass  spectrometry  (MS)  using  dopant-assisted
atmospheric pressure photoionization (APPI) utilized only commercially
available hardware. The developed GC-APPI-MS/MS method provided high
chromatographic resolution and efficient ionization of neurosteroids, which
formed mainly abundant radical cations (M•+) with minimal fragmentation
when chlorobenzene was used as the dopant. The method showed good
specificity  and  sensitivity  and  is  therefore  well  suited  for  the  analysis  of
neurosteroids  in  biological  samples.  The  APPI  interface  provides  an  easy
means  to  couple  GC  to  MS,  allowing  the  high  chromatographic  resolution
capacity of gas chromatography to be exploited with any mass spectrometer
equipped  with  an  atmospheric  pressure  ionization  interface.  The  radical
cations of the steroids formed by APPI ionization showed fragmentation
patterns  in  their  MS/MS  spectra  similar  to  the  patterns  seen  in  the
corresponding EI spectra. Use of EI libraries could thus be possible, enabling
the identification of a wide range of unknown compounds.
The GC-APPI-MS interface was nevertheless a self-made prototype, and
the interface was further developed in order to maximize ion transmission and
thus increase the sensitivity of the method. The presented prototype capillary
photoionization device, CPI, showed good potential as a simple and effective
ion source for the analysis of both polar and nonpolar compounds. Compared
to  the  GC-APPI-MS/MS  method,  which  employed  a  completely  open  ion
source, ion transmission is higher with the CPI device, where the ionization
region is shielded. Further experiments with GC, LC, and other types of mass
spectrometers are needed to demonstrate the full potential of CPI.
SUMMARY AND CONCLUSIONS
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